Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-1,4-N-acetylgalactosaminyltransferase 3 (B4GALNT3) is an enzyme of the chondroitin N-acetylgalactosaminyltransferase family that catalyzes the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to N-acetylglucosamine-containing glycans, forming LacdiNAc (GalNAcβ1-4GlcNAc) structures on N- and probably O-linked glycans[2][3][4][5]. B4GALNT3 contains a unique PA14 domain, critical for its glycan-recognition and catalytic activity[1][3]. Through its enzymatic activity, B4GALNT3 regulates the maturation and terminal modifications (e.g., sialylation, fucosylation) of glycoproteins, thereby affecting protein behavior such as clearance from the bloodstream and cell signaling. Disruption of B4GALNT3 activity alters glycoprotein stability and has been linked to bone loss (via sclerostin regulation) and may have broader implications in glycoprotein-related diseases[3]. The enzyme plays a key role in the biosynthesis of LacdiNAc, impacting various aspects of glycoprotein function and homeostasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-1,4-N-acetylgalactosaminyltransferase 3 (B4GALNT3).